We compared the efficacy of ceftriaxone combined with gentamicin, both given once a day, with that of cloxacillin given every 4 h plus gentamicin given once a day or in three daily doses (t.i.d.) for the treatment of experimental methicillin-susceptible staphylococcal endocarditis. The antibiotics were administered by using human-like (H-L) pharmacokinetics that simulated the profiles of these drugs in human serum. Animals with catheter-induced endocarditis were infected intravenously with 10(5) CFU of Staphylococcus aureus S5 (MICs and minimal bactericidal concentrations of cloxacillin, ceftriaxone, and gentamicin, 0.5 and 2 microg/ml, 4 and 8 microg/ml, and 0.5 and 1 microg/ml, respectively). The animals were then treated for 24 h with cloxacillin at a dose of 2 g that simulated H-L pharmacokinetics (H-L 2 g) every 4 h alone or combined with gentamicin (administered at doses of H-L 1 mg/kg of body weight every 8 h or H-L 4.5 mg/kg every 24 h) or with ceftriaxone at H-L 2 g every 24 h alone or combined with gentamicin (administered at doses of H-L 1 mg/kg every 8 h or H-L 4.5 mg/kg every 24 h). The results of therapy for experimental endocarditis due to the S5 strain showed that (i) cloxacillin alone is more effective than ceftriaxone alone in reducing the bacterial load (P < 0.01), (ii) the combination of cloxacillin or ceftriaxone with gentamicin is more effective than each of these drugs alone (P < 0.01), and (iii) Ceftriaxone H-L plus gentamicin H-L 4.5 mg/kg, both administered every 24 h, showed efficacy similar to that of the "gold standard," cloxacillin H-L plus gentamicin H-L 1 mg/kg t.i.d. (P > 0.05). An increase in the interval of administration of gentamicin to once daily resulted in a reduction in the numbers of bacteria in the vegetations equivalent to that achieved with the recommended regimen of cloxacillin plus gentamicin t.i.d. in the treatment of experimental endocarditis due to methicillin-susceptible S. aureus. Ceftriaxone plus gentamicin, both administered once a day, may be useful for home-based therapy for selected cases of staphylococcal endocarditis.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC127055PMC
http://dx.doi.org/10.1128/AAC.46.2.378-384.2002DOI Listing

Publication Analysis

Top Keywords

h-l mg/kg
24
ceftriaxone gentamicin
16
gentamicin
12
gentamicin day
12
treatment experimental
12
staphylococcal endocarditis
12
combined gentamicin
12
h-l
12
gentamicin administered
12
efficacy ceftriaxone
8

Similar Publications

Background: Osteoarthritis (OA) is a painful degenerative joint disease and a leading source of years lived with disability globally due to inadequate treatment options. Neuroimmune interactions reportedly contribute to OA pain pathogenesis. Notably, in rodents, macrophages in the DRG are associated with onset of persistent OA pain.

View Article and Find Full Text PDF
Article Synopsis
  • Neurofibrillary tangles (NFTs), linked to Alzheimer's disease (AD) neurodegeneration, consist of hyperphosphorylated tau proteins, particularly affecting memory in the hippocampus.* -
  • The study investigated the effects of AL04, a new protein treatment, on lowering hyperphosphorylated tau in a specific mouse model with human tau mutation, revealing significant decreases in tau levels and changes in autophagy-related proteins.* -
  • Findings suggest that AL04 could serve as a potential preventive and therapeutic agent for AD by promoting tau degradation and regulating relevant protein pathways.*
View Article and Find Full Text PDF

Population Pharmacokinetics of Vancomycin in Intensive Care Patients with the Time-Varying Status of Temporary Mechanical Circulatory Support or Continuous Renal Replacement Therapy.

Infect Dis Ther

December 2024

Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, No.1, University Road, Tainan City, 701, Taiwan.

Article Synopsis
  • This study evaluates how vancomycin is processed in critically ill patients, particularly those undergoing continuous renal replacement therapy (CRRT) or temporary mechanical circulatory support (tMCS).
  • The research involved 25 patients and focused on how factors like serum creatinine and body weight influence drug clearance and distribution.
  • It concludes that vancomycin dosing should consider both renal function and body weight, suggesting modified initial and maintenance doses for patients on CRRT, while also noting that tMCS can complicate dosing adjustments due to altered drug clearance.
View Article and Find Full Text PDF
Article Synopsis
  • Invasive aspergillosis (IA) and mucormycosis (IM) significantly affect severely ill patients, prompting the approval of isavuconazonium sulfate for treating these fungal infections in both adults and recently in children.
  • A phase 2 study involved 31 pediatric patients across multiple countries, revealing a 54.8% overall response rate to treatment and a low 6.5% all-cause case fatality at 42 days.
  • Although 93.5% of participants experienced treatment-emergent adverse events (TEAEs), the drug was generally well tolerated, and dosing conformed to safety standards previously established in adult studies.
View Article and Find Full Text PDF

This was a multicenter, single-arm, open-label, phase Ib/II study (NCT04255576), aimed to evaluate the efficacy and safety of JMT103 in patients with unresectable or surgically-challenging giant cell tumor of bone (GCTB). JMT103 (2 mg/kg) was administered subcutaneously every four weeks, with loading doses on days 8 and 15. The primary endpoint was the objective tumor response rate (OTR) based on best response, defined as the proportion of patients who achieved elimination of at least 90% of the giant cells or radiologic complete or partial response per the modified Inverse Choi density/size (mICDS) or modified European Organization for Research and Treatment of Cancer (mEORTC) within 12 weeks.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!